Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies With an IDH2 Mutation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced dose administration for the first patient in a Phase 1 study of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is an oral, selective, potent inhibitor of the mutated IDH2 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor IDH2 mutations.

Help employers find you! Check out all the jobs and post your resume.